Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.

Article Details

Citation
Copy to clipboard

Bell AM, Wagner JL, Barber KE, Stover KR

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.

Int J Hepatol. 2016;2016:3852126. doi: 10.1155/2016/3852126. Epub 2016 Jun 15.

PubMed ID
27403342 [ View in PubMed
]
Abstract

Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C.

DrugBank Data that Cites this Article

Drugs